Anna Berkenblit
2020
In 2020, Anna Berkenblit earned a total compensation of $1.6M as Senior Vice President and Chief Medical Officer at ImmunoGen, a 12% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $152,131 |
|---|---|
| Option Awards | $958,326 |
| Salary | $480,233 |
| Other | $9,372 |
| Total | $1,600,062 |
Berkenblit received $958.3K in option awards, accounting for 60% of the total pay in 2020.
Berkenblit also received $152.1K in non-equity incentive plan, $480.2K in salary and $9.4K in other compensation.
Rankings
In 2020, Anna Berkenblit's compensation ranked 6,553rd out of 13,090 executives tracked by ExecPay. In other words, Berkenblit earned more than 49.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,553 out of 13,090 | 50th |
Division Manufacturing | 2,710 out of 5,621 | 52nd |
Major group Chemicals And Allied Products | 1,091 out of 2,254 | 52nd |
Industry group Drugs | 945 out of 1,954 | 52nd |
Industry Pharmaceutical Preparations | 706 out of 1,459 | 52nd |
Source: SEC filing on April 28, 2021.
Berkenblit's colleagues
We found four more compensation records of executives who worked with Anna Berkenblit at ImmunoGen in 2020.